Last updated on November 2019

3-year Study in Dry Eye Disease Patients With Severe Keratitis Receiving Ikervis (1mg/mL Ciclosporin)


Brief description of study

The proposed 36-month Post Approval Efficacy Study (PAES) is a prospective, interventional, multicentre study to explore the long-term evolution of signs and symptoms, and occurrence of complications in Dry Eye Disease (DED) patients with severe keratitis receiving Ikervis (1mg/mL ciclosporin) eye drops administered once daily

Clinical Study Identifier: NCT04144413

Find a site near you

Start Over